Menke-van der Houven van Oordt, C Willemien <br/><br/>
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.  [electronic resource] 

 -  Oncotarget  Nov 2016 
 - 80046-80058 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.11098  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Antineoplastic Agents, Immunological--adverse effects<br/>Disease Progression<br/>Female<br/>Humans<br/>Hyaluronan Receptors--genetics<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Pilot Projects<br/>Positron-Emission Tomography<br/>Radiopharmaceuticals--pharmacokinetics<br/>Tissue Distribution<br/>Zirconium--pharmacokinetics